Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655551 · ClinicalTrials.gov registry record · Phase 3
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00655551 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 100 participants.
The verdict
NCT00655551, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
Interventions
- DRUG lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655551
The ClinicalTrials.gov registry entry for NCT00655551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lacosamide is the first listed.
NCT00655551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655551 about?
NCT00655551 is a clinical study titled "Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures". The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
What is the current status of trial NCT00655551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00655551?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00655551?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.